WB
H M
Endogenous
550
Rabbit
#Q14517
2195
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse
Species predicted to react based on 100% sequence homology
The antigen sequence used to produce this antibody shares
100% sequence homology with the species listed here, but
reactivity has not been tested or confirmed to work by CST.
Use of this product with these species is not covered under
our
Product Performance Guarantee.
Rat
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human FAT1 protein. Antibodies are purified by peptide affinity chromatography.
Background
FAT1 is a member of the FAT atypical cadherin (FAT) subfamily of cadherin proteins (1). FAT1 is a single-pass transmembrane protein, first identified in a screen for tumor suppressor proteins in Drosophila (2). FAT1 is expressed primarily in epithelial cells, where it plays a prominent role in regulating cell growth and migration, in large part through the regulation of cell-cell adhesion dynamics (3). The intracellular cytoplasmic tail of FAT1 contains multiple functional motif/domains that regulate FAT1 functions, including a proline rich EVH1 binding motif that regulates actin cytoskeleton components (e.g., Ena/VASP proteins) at both cell-cell contact points and leading edges of migrating cells (4,5). FAT1 appears to play a role in linking cell adhesion events to intracellular signaling pathways. For example, FAT1 was capable of inhibiting the nuclear translocation of β-catenin through its cytoplasmic FC1 domain interaction with β-catenin (6), and activating the Hippo signaling pathway, suppressing YAP signaling by its N-terminal cytoplasmic region interaction with MST1 (7). Research studies have revealed that the tumor suppressor functions identified in Drosophila are conserved in vertebrate FAT1 homologs (8). For example, studies in human cancer cells showed that loss-of-function mutations in the gene encoding FAT1 promoted a hybrid epithelial-to-mesenchymal transition, which further enabled the development of cancer drug resistance (9). Notably, studies have also revealed an oncogenic function for FAT1 in some contexts (10).
- Tanoue, T. and Takeichi, M. (2005) J Cell Sci 118, 2347-53.
- Mahoney, P.A. et al. (1991) Cell 67, 853-68.
- Moeller, M.J. et al. (2004) EMBO J 23, 3769-79.
- Tanoue, T. and Takeichi, M. (2004) J Cell Biol 165, 517-28.
- Hou, R. et al. (2006) J Cell Biol 173, 417-29.
- Martin, D. et al. (2018) Nat Commun 9, 2372.
- Morris, L.G. et al. (2013) Nat Genet 45, 253-61.
- Pastushenko, I. et al. (2021) Nature 589, 448-455.
- Peng, Z. et al. (2021) Oncol Lett 21, 398.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.